Skip to main content

The medicine Retevmo selpercatinib is recommended by healthcare professionals to treat patients with advanced or metastatic non-small cell lung cancer, thyroid cancer, and solid tumors with a RET gene fusion. The FDA approved this drug in 2020, usually in 40 mg and 80 mg capsule form for oral administration. 

Non-small cell lung cancer (NSCLC): Introduction

Non-small cell lung cancer happens when abnormal cells form and multiply in your lung tissues. NSCLC is 1 of 2 main types of lung cancer. The other is small-cell lung cancer. There are 3 main types of NSCLC:

  • Adenocarcinoma
  • squamous cell
  • Large cell carcinoma

Note: NSCLC is the most common type of lung cancer, summing up about 85% of all lung cancer cases.

Symptoms of NSCLC

The most common warning signs for NSCLC are; shortness of breath and a cough that doesn’t go away. Other NSCLC symptoms might be:

  • Chest pain or discomfort.
  • A cough that doesn’t go away or gets worse over time.
  • Trouble breathing.
  • Wheezing.
  • Coughing up blood.
  • Loss of hunger.
  • Weight loss for no known reason.
  • Tiredness.
  • Hoarseness.
  • Difficulty swallowing.
  • Swelling in the face or the veins in the neck.
  • At times, lung cancer doesn’t cause any symptoms and is discovered during routine X-rays or screenings.

Diagnosis of NSCLC

The healthcare professional performs a physical examination and asks about the signs and health history. If they suspect NSCLC, they’ll recommend certain tests to diagnose and stage the disease. These tests may include:

  • Laboratory tests: blood or urine analyses.
  • Chest X-rays
  • CT scans
  • Biopsy 
  • Sputum cytology
  • Bronchoscopy
  • Thoracoscopy
  • Thoracentesis

Recommended dosage: Retevmo

The recommended Retevmo dosage based on body weight is: 

  • Less than 50 kg: 120 mg 
  • 50 kg or greater: 160 mg 

Take Retevmo orally twice daily until disease progression or unacceptable toxicity. Swallow the capsules whole. Do not crush or chew the capsules.


Nitin Goswami

Nitin Goswami joined us as an Editor in 2020. He covers all the updates in the field of Pharmaceutical, Business Healthcare, Health News, Medical News, and Pharma News.

Leave a Reply

Close Menu